David Budd, CEO, Genedrive PLC (LON:GDR)

We caught up with Manchester based company Genedrive PLC and spoke with David Budd about the company progress and what he has planned for the future.

 Decentralising molecular diagnostics

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. We are passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by Global Health issues.

Genedrive® development has been validated through a range of applications and external independent evaluations. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and the Asia Pacific region. genedrive plc has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and selected countries of the Asia Pacific region, and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India. The company also has an active development programme underway for Tuberculosis detection and drug resistance assessment.

genedrive plc is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With an historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.